Hanmi Licenses Muscle-Preserving Obesity Drug Candidate to Genentech in $2.3 Billion Deal
Hanmi Pharmaceutical has entered into an exclusive global licensing agreement with Genentech, a member of the Roche Group, for its next-generation...
Search results for "technology transfer"
South Korea Overhauls Pharma and Biotech Disclosure Rules Following Samchundang Controversy
South Korean financial authorities are overhauling disclosure regulations across the pharmaceutical and biotechnology sectors to curb exaggerated...
Eli Lilly Licensing Deal Surge: Hanmi Pharmaceutical’s Q2 Operating Profit Jumps 117%
Hanmi Pharmaceutical posted a sharp profit surge in the second quarter of this year, buoyed by a major...
Landmark Biotech Deal: Celltrion Acquires Autoimmune Disease Antibody Tech from Catholic University of Korea
A research team led by Kim Wan-wook at the Catholic University of Korea College of Medicine has successfully...
Fueling the Future of Biohealth: InterBiz Forum Opens in Jeju With a Record 1,500 Tech Deals
The 24th InterBiz Bio Partnering & Investment Forum 2026, a premier biohealth technology deal-making event, opened...
Yuhan Outlines Clinical Progress for Oral Targeted Anticancer Candidate YH42946 at WCLC 2026
Yuhan Corporation has detailed the status and trial design of the ongoing Phase 1/2 clinical study for YH42946, an oral...
Beyond Diseased Samples: National Biobank to Collect Healthy Organ Tissue from Deceased Donors
When a specific gene or protein is expressed at unusually high levels in diseased tissue, determining whether the...
Beyond Medical Missions: Asan Medical Center Empowers Mongolian Doctors to Achieve Self-Reliance
For residents of northern Mongolia living more than 400 kilometers from the capital, Ulaanbaatar, accessing specialized...
South Korea to Deploy AI Across Public Health Centers and Ambulances to Close Care Gaps
Artificial intelligence tools that assist in interpreting X-ray images and drafting clinical notes will soon be...
Alteogen Signs $365 Million Licensing Deal for Subcutaneous Drug Delivery Platform ALT-B4
Biotechnology firm Alteogen has signed an exclusive technology-transfer agreement worth up to $365 million...